Content matching 'cell therapy approval'
Cell therapy weekly: Scott Gottlieb resigns from FDA and Japan to commence iPSC trial for corneal disease
Overcoming the obstacles to a commercially successful cell or gene therapy: an interview with Dr Nafees Malik
Member Exclusive INTERVIEW
Latest news & views, Spotlight on allogeneic CAR-T, Spotlight on gene therapy, Spotlight on immunotherapy, Spotlight on commercialization and translation, Spotlight on cell therapy regulation, Cell therapy, Manufacturing & scale-up, Ethics & policy, Industry developments
Cell therapy weekly: New biotech focused on engineered cells licenses Harvard tech
Editor’s highlights: Opportunities and Challenges in Translating Cell and Gene Therapy Products
The commercialization of cell and gene therapies: regulatory challenges
Cell therapy weekly: Kymriah could be available in Japan and stem cells show benefits against multiple sclerosis
The Regulation of Clinical Stem Cell Research and Applications: three dynamics of global regulatory diversification (part 1)
The buzz at the Phacilitate Cell & Gene Therapy Forum in Washington DC on 26 to 28 January was that gene therapy will become a mainstream activity in the global pharmaceutical industry over the next five years, driven in part by the new gene-modified cell therapies and genome editing.
Keeping patients safe from unproven cell therapies: an interview with the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies